Clin2
NCT06610695Possibly a fitEnrolling by invitation

Bile acid PET/CT scan for genetic liver disorders

CholestasisGenetic Liver Disorder

Part of Digestive system clinical trials.

This study uses a special PET/CT scan with a tracer called 11C-Csar, which is similar to bile acid, to see how well your liver handles bile. It is for healthy people and those with genetic liver diseases that cause cholestasis (slowed bile flow). The goal is to improve diagnosis and understanding of these conditions.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
22 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You are 18 years or older.
  • You have no known liver disease (if healthy) OR you have cholestasis (elevated ALP or bilirubin) not caused by a physical blockage (if patient).
  • You do not take any medications that affect your liver or bile system (if healthy).
  • You are not pregnant and can have a negative pregnancy test on scan day.
  • You do not have claustrophobia and can lie still for 45 minutes.
  • You have not had your gallbladder removed (cholecystectomy).
  • You are willing and able to give signed consent on the scan day.
  • You do not have a blood clotting problem that would prevent a liver vein catheter (if patient).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05359939Recruiting
MRI, CT, and PET scans compared for liver cancer

This study compares different scan types (MRI, CT, and two PET scans) in people with hepatocellular carcinoma (a primary liver cancer). It may help doctors figure out which scan gives the most useful information for diagnosis and treatment planning.

Aarhus
NCT05871892Recruiting
PET/CT or PET/MRI scans for suspected or diagnosed liver cancer

This study looks at how well special imaging scans (PET/CT or PET/MRI) work in adults with suspected or diagnosed liver cancer. It may help doctors better see the cancer and plan next steps.

Aarhus
NCT07673341Not yet recruiting· Phase 2
PET scan to predict response in bile duct cancer

This study tests whether a special PET scan (using [18F]FTT) can predict how well the standard GCD chemotherapy and immunotherapy combination will work for newly diagnosed bile duct cancer. The scan helps doctors see tumor activity before treatment.

Seattle, Washington
NCT06355427Recruiting· Phase 2/Phase 3
New PET scan for bile duct cancer before surgery

This trial tests a new type of PET-CT scan (called FAPI) to see if it helps doctors better decide treatment for people with bile duct cancer that can be surgically removed. It may help avoid unnecessary surgery if the scan shows the cancer has spread.

Amsterdam
NCT06252610Not yet recruiting
PET/MRI study for primary sclerosing cholangitis (PSC)

This study uses a PET/MRI scan to take detailed pictures of the liver and bile ducts in people with PSC. The goal is to better understand the disease and possibly find new ways to track it.

Charlestown, Massachusetts
NCT07590336Not yet recruiting· Phase 1/Phase 2
Advanced imaging scan for liver cancer detection

This study tests a new type of imaging scan (called 68Ga-NYM207 PET/CT) that may help doctors better find and understand liver cancer. You would receive the scan once to see if it helps doctors plan your treatment or monitor your cancer.

Beijing

Hear when a new Cholestasis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.